<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/C0E4FAD2-3C8B-410A-B6DF-3B9B9E433060"><gtr:id>C0E4FAD2-3C8B-410A-B6DF-3B9B9E433060</gtr:id><gtr:name>University of St Andrews</gtr:name><gtr:department>Biology</gtr:department><gtr:address><gtr:line1>College Gate</gtr:line1><gtr:line4>St. Andrews</gtr:line4><gtr:line5>Fife</gtr:line5><gtr:postCode>KY16 9AJ</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/C0E4FAD2-3C8B-410A-B6DF-3B9B9E433060"><gtr:id>C0E4FAD2-3C8B-410A-B6DF-3B9B9E433060</gtr:id><gtr:name>University of St Andrews</gtr:name><gtr:address><gtr:line1>College Gate</gtr:line1><gtr:line4>St. Andrews</gtr:line4><gtr:line5>Fife</gtr:line5><gtr:postCode>KY16 9AJ</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/05B94338-C10A-4B86-B943-018DA740A8EC"><gtr:id>05B94338-C10A-4B86-B943-018DA740A8EC</gtr:id><gtr:firstName>Martin</gtr:firstName><gtr:otherNames>Denis</gtr:otherNames><gtr:surname>Ryan</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0901002"><gtr:id>9E697C76-5095-4CDD-9468-702C025B1B56</gtr:id><gtr:title>Optimisation of the 2A Co-expression System for Gene Therapies</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0901002</gtr:grantReference><gtr:abstractText>Gene therapy supplies your cells with genes either to replace faulty ones, or to supply genes that can combat other forms of disease. These genes are then translated into proteins. Often, however, a number of different proteins (and hence genes) are required for successful therapy. This work is designed to develop a system whereby multiple genes can be strung together to form a single gene: a multi-gene. It is much easier and safer to introduce one gene via gene therapy, than try to introduce many individual genes into a cell. The chances of this new type of multi-gene being able to produce all of its different proteins (and all at the same time) is very much higher than is the case with many individual genes. The methods we wish to develop here will extend the range of diseases that may be treated by gene therapy.</gtr:abstractText><gtr:technicalSummary>2A and 2A-like sequences are short, oligopeptide, sequences that mediate a co-translational cleavage at their own C-termini: they are used in gene therapy and other biomedical applications to concatenate multiple cistrons into a single open reading frame. Multiple proteins may, therefore, be co-expressed using from single transgene. We have discovered that sequences immediately upstream of 2A may inhibit the cleavage of proteins targeted to the exocytic pathway. Since ~40% of human proteins are (at least initially) translocated into the ER, gene therapies will inevitably involve the co-expression of such proteins. Our data strongly suggest an interaction between the nascent protein and the translocon pore is responsible for this inhibition. This application seeks to perform a fine mapping of the inhibitory interactions and through a program of screening site-directed mutants/insertions to identify methods of achieving high-level 2A-mediated cleavage of such proteins. The partition of proteins (derived from 2A-mediated cleavage)between the exocytic pathway and the cytoplasm will be measured to compare the the relative efficiencies of different 2A-linker sequences. The aim is to develop the technology to provide gene therapists with a complete tool-kit for protein co-expression.</gtr:technicalSummary><gtr:fund><gtr:end>2013-05-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2010-06-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>343784</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Mutations have been made in the 2A oligopeptide sequence which alter the 'cleavage' activity (producing different levels of translational 'recoding'). These clones have been made freely available to other researchers. Guides how to use the 2A protein co-expression system and a bibliography of '2A-users' (plus the different applications of 2A) and maintained and continulally updated on my research web pages.</gtr:description><gtr:id>738D687A-401D-494F-926B-693D569F0E05</gtr:id><gtr:impact>The 2A sequence has been used very widely in biomedicine e.g cancer gene therapies (adodptive cell therapies), production of human pluripotent stem cells, genome editing technologies, etc. We continue to refine this system and to identify new 2A-like sequences to improve the 2A-mediated co-expression of multiple proteins within the same cell.</gtr:impact><gtr:outcomeId>nxCm73imgn7</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>cDNA clones</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:url>http://www.st-andrews.ac.uk/ryanlab/Index.htm</gtr:url><gtr:yearFirstProvided>2011</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>64B4FE9D-9C25-4487-BA2D-67F3D56AAF41</gtr:id><gtr:title>Inhibition of the foot-and-mouth disease virus subgenomic replicon by RNA aptamers.</gtr:title><gtr:parentPublicationTitle>The Journal of general virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fdd956acf2cbdc15ced38e5429a2f68c"><gtr:id>fdd956acf2cbdc15ced38e5429a2f68c</gtr:id><gtr:otherNames>Forrest S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0022-1317</gtr:issn><gtr:outcomeId>585d496aea0202.83726889</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1B33ABB1-56F9-4093-A664-03B14358393A</gtr:id><gtr:title>Employing transposon mutagenesis to investigate foot-and-mouth disease virus replication.</gtr:title><gtr:parentPublicationTitle>The Journal of general virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7f91ecfe62149449f8632ab22b64ba6e"><gtr:id>7f91ecfe62149449f8632ab22b64ba6e</gtr:id><gtr:otherNames>Herod MR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0022-1317</gtr:issn><gtr:outcomeId>585d749f3ec4b4.86718629</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D988FCA2-F33B-4C7E-8D8F-D1C921C8B975</gtr:id><gtr:title>APE-type non-LTR retrotransposons of multicellular organisms encode virus-like 2A oligopeptide sequences, which mediate translational recoding during protein synthesis.</gtr:title><gtr:parentPublicationTitle>Molecular biology and evolution</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b3dfd42e3fca5256bf4dd9f7f7ad3698"><gtr:id>b3dfd42e3fca5256bf4dd9f7f7ad3698</gtr:id><gtr:otherNames>Odon V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0737-4038</gtr:issn><gtr:outcomeId>doi_55f94c94c074b546</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CB799B29-6213-4999-8D13-6A38F4F69768</gtr:id><gtr:title>Evaluating the use of HILIC in large-scale, multi dimensional proteomics: Horses for courses?</gtr:title><gtr:parentPublicationTitle>International journal of mass spectrometry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/48f71b0410de11b05180b334e6549df3"><gtr:id>48f71b0410de11b05180b334e6549df3</gtr:id><gtr:otherNames>Bensaddek D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1387-3806</gtr:issn><gtr:outcomeId>5a2fcbedd8a129.27918730</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2726C281-36B9-4507-A6E5-5FF4053E8E38</gtr:id><gtr:title>Proteomic analysis of the response to cell cycle arrests in human myeloid leukemia cells.</gtr:title><gtr:parentPublicationTitle>eLife</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0e97d42c8bd4d79d4d09e6b6f98a540e"><gtr:id>0e97d42c8bd4d79d4d09e6b6f98a540e</gtr:id><gtr:otherNames>Ly T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2050-084X</gtr:issn><gtr:outcomeId>5a2fcbb2008fa8.62099354</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CFCD763A-4309-4834-90EA-07BA21B1FD48</gtr:id><gtr:title>An Interferon Regulated MicroRNA Provides Broad Cell-Intrinsic Antiviral Immunity through Multihit Host-Directed Targeting of the Sterol Pathway.</gtr:title><gtr:parentPublicationTitle>PLoS biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/63fe928fe95366d3f57197c8e7f1ae4a"><gtr:id>63fe928fe95366d3f57197c8e7f1ae4a</gtr:id><gtr:otherNames>Robertson KA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1544-9173</gtr:issn><gtr:outcomeId>5a31a134aff4a3.15531894</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>657501F4-2680-4A45-80FC-BF1C05B85E7B</gtr:id><gtr:title>Characterization of native protein complexes and protein isoform variation using size-fractionation-based quantitative proteomics.</gtr:title><gtr:parentPublicationTitle>Molecular &amp; cellular proteomics : MCP</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1e61d636e83481ebabac6b8f148cb19e"><gtr:id>1e61d636e83481ebabac6b8f148cb19e</gtr:id><gtr:otherNames>Kirkwood KJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1535-9476</gtr:issn><gtr:outcomeId>5a322e41c3af17.48495828</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>356C12B4-7E26-4751-8EE9-3F1E082EC7E4</gtr:id><gtr:title>Optimisation of the 'FMDV' 2A Co-Expression System for Gene Therapies</gtr:title><gtr:parentPublicationTitle>MOLECULAR THERAPY</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7d99fd66d4845336eb4fa7781c0bd90f"><gtr:id>7d99fd66d4845336eb4fa7781c0bd90f</gtr:id><gtr:otherNames>Minskaia Ekaterina</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1525-0016</gtr:issn><gtr:outcomeId>N4hSRBWwTt4</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>627E12B4-231E-4803-BCAC-308F65988BCE</gtr:id><gtr:title>FMDV replicons encoding green fluorescent protein are replication competent.</gtr:title><gtr:parentPublicationTitle>Journal of virological methods</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f2cec68cefdd99d3b0d98b46a0491e2e"><gtr:id>f2cec68cefdd99d3b0d98b46a0491e2e</gtr:id><gtr:otherNames>Tulloch F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0166-0934</gtr:issn><gtr:outcomeId>doi_55f94d94de0c4087</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E32BF785-9365-4F1A-8CE2-3D916FEA2832</gtr:id><gtr:title>'2A-Like' Signal Sequences Mediating Translational Recoding: A Novel Form of Dual Protein Targeting.</gtr:title><gtr:parentPublicationTitle>Traffic (Copenhagen, Denmark)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/af746e88ad17e9819b663c758c2a3285"><gtr:id>af746e88ad17e9819b663c758c2a3285</gtr:id><gtr:otherNames>Roulston C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1398-9219</gtr:issn><gtr:outcomeId>585d495cc91519.69721903</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6ECD4706-729E-4099-A431-C160ED9EF4CF</gtr:id><gtr:title>Both cis and trans Activities of Foot-and-Mouth Disease Virus 3D Polymerase Are Essential for Viral RNA Replication.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7f91ecfe62149449f8632ab22b64ba6e"><gtr:id>7f91ecfe62149449f8632ab22b64ba6e</gtr:id><gtr:otherNames>Herod MR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>585d3d8fdecfc1.85282582</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3C25BB15-5657-4A9F-AE0D-994F9F15C12C</gtr:id><gtr:title>A proteomic chronology of gene expression through the cell cycle in human myeloid leukemia cells.</gtr:title><gtr:parentPublicationTitle>eLife</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0e97d42c8bd4d79d4d09e6b6f98a540e"><gtr:id>0e97d42c8bd4d79d4d09e6b6f98a540e</gtr:id><gtr:otherNames>Ly T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>2050-084X</gtr:issn><gtr:outcomeId>5a2fcb95d36a92.32704036</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2ED09E20-175E-462F-912A-9030DF6ACA30</gtr:id><gtr:title>Attenuation of dengue (and other RNA viruses) with codon pair recoding can be explained by increased CpG/UpA dinucleotide frequencies.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/08733c014523f53ca3708169146f11f4"><gtr:id>08733c014523f53ca3708169146f11f4</gtr:id><gtr:otherNames>Simmonds P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>585d3901423f62.83148251</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C2C6D643-49C4-4820-AD84-F276F11A960A</gtr:id><gtr:title>RNA virus attenuation by codon pair deoptimisation is an artefact of increases in CpG/UpA dinucleotide frequencies.</gtr:title><gtr:parentPublicationTitle>eLife</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f2cec68cefdd99d3b0d98b46a0491e2e"><gtr:id>f2cec68cefdd99d3b0d98b46a0491e2e</gtr:id><gtr:otherNames>Tulloch F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>2050-084X</gtr:issn><gtr:outcomeId>doi_55f94d94de197324</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1A5B8EE7-722C-4D58-B7CC-3EEC2EFB2D4E</gtr:id><gtr:title>2A peptides provide distinct solutions to driving stop-carry on translational recoding.</gtr:title><gtr:parentPublicationTitle>Nucleic acids research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fa4f74f53bb7d95f85e452140087cce0"><gtr:id>fa4f74f53bb7d95f85e452140087cce0</gtr:id><gtr:otherNames>Sharma P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0305-1048</gtr:issn><gtr:outcomeId>doi_55f94a94aa0df07d</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8D40DF25-3960-43E3-A715-78DE94D38FDE</gtr:id><gtr:title>Genetic economy in picornaviruses: Foot-and-mouth disease virus replication exploits alternative precursor cleavage pathways.</gtr:title><gtr:parentPublicationTitle>PLoS pathogens</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7f91ecfe62149449f8632ab22b64ba6e"><gtr:id>7f91ecfe62149449f8632ab22b64ba6e</gtr:id><gtr:otherNames>Herod MR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1553-7366</gtr:issn><gtr:outcomeId>5a2fcd6bb5dd09.01442812</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0901002</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>F3822669-BB5A-4BB4-BAE0-DCB9DE36E092</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Generic Health Relevance</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>DD81206B-5EB4-4BCC-AEF7-808A64606E0E</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>5.2  Cellular and gene therapies</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>